Use of anti-TREM1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders

Anti-TREM1 antibodies target TREM1 to mitigate neuroinflammation and microglial activation, effectively slowing ALS progression by reducing inflammation in the brain and spinal cord.

JP7894368B2Inactive Publication Date: 2026-07-23UCB BIOPHARMA SPRL
View PDF 4 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
UCB BIOPHARMA SPRL
Filing Date
2020-11-02
Publication Date
2026-07-23
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for amyotrophic lateral sclerosis (ALS) do not effectively address the multifactorial neuroinflammation driven by microglial activation and TREM1-enhanced neurotoxic responses, which contribute to motor neuron degeneration.

Method used

Administration of anti-TREM1 antibodies or their antigen-binding fragments to neutralize TREM1, reducing microglial neuronal uptake, pro-inflammatory cytokine release, and microglial migration, thereby attenuating brain and spinal cord inflammation in ALS models.

Benefits of technology

The anti-TREM1 antibodies significantly reduce inflammation and slow the progression of ALS by decreasing microglial activity and inflammation in the brain and spinal cord, providing therapeutic benefits in preclinical models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007894368000006
    Figure 0007894368000006
  • Figure 0007894368000007
    Figure 0007894368000007
  • Figure 0007894368000008
    Figure 0007894368000008
Patent Text Reader

Abstract

The present invention provides antibodies, or antigen-binding fragments thereof, that bind to and neutralize TREM1 for use in treating motor neuron degenerative disorders, particularly amyotrophic lateral sclerosis.
Need to check novelty before this filing date? Find Prior Art